Z

Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456

Watchlist Manager
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Watchlist
Price: 15.57 CNY -0.19% Market Closed
Market Cap: 14B CNY
Have any thoughts about
Zhejiang Jiuzhou Pharmaceutical Co Ltd?
Write Note

Zhejiang Jiuzhou Pharmaceutical Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhejiang Jiuzhou Pharmaceutical Co Ltd
Cash & Cash Equivalents Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zhejiang Jiuzhou Pharmaceutical Co Ltd
SSE:603456
Cash & Cash Equivalents
ÂĄ2.8B
CAGR 3-Years
54%
CAGR 5-Years
69%
CAGR 10-Years
32%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash & Cash Equivalents
ÂĄ22.4B
CAGR 3-Years
74%
CAGR 5-Years
103%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash & Cash Equivalents
ÂĄ8.8B
CAGR 3-Years
59%
CAGR 5-Years
21%
CAGR 10-Years
24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash & Cash Equivalents
ÂĄ22.3B
CAGR 3-Years
22%
CAGR 5-Years
39%
CAGR 10-Years
23%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash & Cash Equivalents
ÂĄ14.1B
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
21%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash & Cash Equivalents
ÂĄ391.7m
CAGR 3-Years
105%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Zhejiang Jiuzhou Pharmaceutical Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.8B CNY

Based on the financial report for Jun 30, 2024, Zhejiang Jiuzhou Pharmaceutical Co Ltd's Cash & Cash Equivalents amounts to 2.8B CNY.

What is Zhejiang Jiuzhou Pharmaceutical Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
32%

Over the last year, the Cash & Cash Equivalents growth was -29%. The average annual Cash & Cash Equivalents growth rates for Zhejiang Jiuzhou Pharmaceutical Co Ltd have been 54% over the past three years , 69% over the past five years , and 32% over the past ten years .

Back to Top